Russia approves its 2nd coronavirus vaccine, EpiVacCorona after the Sputnik V vaccine, which made headlines in media months ago. Russian President Vladimir Putin made the announcement today on a televised government meeting. Developed by the Vector Institute in Siberia, one of the world's most popular virus research centres, the officials claim that EpiVacCorona vaccine is quite different from Sputnik. They have a history of successfully developing vaccines against other deadly viruses like Ebola over their 40 years of working.
The volunteers are injected with two doses of EpiVacCorona. The experiments on the COVID-19 vaccine in Vector institute was begun since March itself. The result of the vaccine which was given to 14 persons in the first phase and 43 persons in the second phase is yet to be published. Like Sputnik V, EpiVacCorona vaccine has also been approved without completing the 3rd phase of the human trail. At the same time, there are indications that the 3rd phase of the trial which involves 30,000 people will take place soon.
The production of the EpiVacCorona vaccine is expected to begin later of this year. " We now need to increase the production of both the first and second vaccine," President said to the media. He also added that its cooperation with their foreign partners is still ongoing and the vaccine Russia has produced will be exported to other foreign countries.